The Once-a-Month Pill: Nortiva Bio's Bid to Reshape Modern Medicine

LEXINGTON, MA – June 18, 2026 – The daily ritual of taking a pill, a cornerstone of modern healthcare for decades, may be on the verge of a profound transformation. Today, Nortiva Bio officially launched from a foundation of cutting-edge science and strategic capital, promising to develop oral medicines that need to be taken not every day, but as little as once a month. Armed with a novel drug delivery platform born at MIT and a heavyweight advisory board, the company is making a high-stakes play to solve one of medicine’s most persistent problems: patient adherence.

Nortiva, a new wholly owned subsidiary of the biopharmaceutical company Innoviva, Inc., is built around the LYNX™ drug delivery platform. This technology aims to package small-molecule drugs into a standard-sized capsule that, once swallowed, can deliver a steady, controlled dose of medication for up to a month. The potential implications are vast, promising to optimize drug efficacy, reduce side effects, and fundamentally change the patient experience across a wide range of diseases.

"Long-acting oral medicines have the potential to meaningfully reshape how patients manage their health and lead to better outcomes," said Austin Hackett, MD, President of Nortiva Bio, in a statement. The company’s launch isn’t just a new corporate entity; it represents the revival and strategic repositioning of a technology that has been years, and hundreds of millions of dollars, in the making.

The Science of Staying Power

At the heart of Nortiva's ambitious plan is the LYNX platform, a marvel of bioengineering that originated in the labs of MIT’s renowned pioneers Robert Langer and Giovanni Traverso. The system is deceptively simple in concept: a patient swallows a standard gelatin capsule containing a star-shaped structure. Once it reaches the stomach, the capsule dissolves and the structure unfolds, its arms making it large enough to be retained in the stomach for an extended period while still allowing food to pass normally.

Each arm of the star contains a polymer matrix loaded with the active drug. Over a programmed period—from a week to a month—stomach fluid slowly permeates the polymer, releasing the drug at a consistent, stable rate. This avoids the “peak and trough” effect common with daily pills, where drug levels spike after dosing and fall before the next one. By maintaining a steady therapeutic level, LYNX has the potential to reduce side effects associated with high drug peaks and prevent efficacy loss from low troughs. Once the drug is fully delivered, the structure’s biodegradable linkers dissolve, the arms break apart, and the small components safely pass through the GI tract.

This isn't just a theoretical concept. The platform's credibility is anchored by robust clinical data generated by its previous owner, Lyndra Therapeutics. The press release mentions a “successful Phase 3 study,” which research confirms refers to the STARLYNG-1 trial for LYN-005, a once-weekly oral version of risperidone for schizophrenia. The study successfully demonstrated that the weekly oral formulation could achieve comparable blood concentration levels to the daily pill, a critical proof-of-concept for the platform's viability. With more than 270 individuals dosed in clinical studies, the technology is far from nascent.

A Strategic Phoenix: The Business Behind the Breakthrough

Nortiva Bio’s launch is also a story of strategic resurrection. The LYNX platform was developed by Lyndra Therapeutics, which raised over $380 million after spinning out of MIT in 2015. However, despite its clinical progress, Lyndra ceased operations in early 2025 after failing to secure the significant financing needed for a pivotal Phase 3 safety study. The episode underscores the brutal capital demands of late-stage drug development.

Innoviva, a diversified biopharma company with a strong balance sheet, stepped in. In September 2025, it acquired the LYNX platform and related assets for a reported $10.2 million upfront, plus potential milestones and royalties. By creating Nortiva Bio as a wholly owned subsidiary and retaining key scientific talent from Lyndra, Innoviva has provided the platform with a stable, long-term financial runway, insulating it from the pressures of venture capital financing.

"The LYNX platform attracted us with its potential to address significant unmet medical needs,” said Pavel Raifeld, CEO of Innoviva. This move signals Innoviva's strategic pivot into highly innovative drug delivery, a space ripe for disruption. Nortiva's business model is twofold: advance its own proprietary lead program while simultaneously forging partnerships with other pharmaceutical companies. This allows partners to create long-acting oral versions of their own blockbuster drugs, potentially extending patent life and creating powerful market differentiators in competitive therapeutic areas.

To guide this strategy, Nortiva has assembled a formidable advisory board that reads like a who's who of the industry. It includes the platform's original inventors, Langer and Traverso, alongside former FDA Commissioner Janet Woodcock, and pharmaceutical business leaders from Merck, Roche, and Kallyope. This collection of expertise provides Nortiva with unparalleled insight into scientific development, regulatory navigation, and commercial strategy.

A Mission-Driven Launchpad: The Once-Monthly Contraceptive

Nortiva is not just building a platform; it is immediately deploying it to address a critical global health challenge. Its lead development program is a once-monthly oral contraceptive, a project bolstered by a $5 million grant from the Bill & Melinda Gates Foundation. This choice of a first asset is both a powerful proof point for LYNX and a mission-driven commitment.

Poor adherence to daily oral contraceptives is a major global issue. Studies show that roughly half of all women on the pill miss at least one dose per month, a lapse that significantly reduces its efficacy and contributes to unintended pregnancies. A convenient, “set-it-and-forget-it” monthly pill could be a game-changer for family planning, both in developed nations and, crucially, in low-resource communities where access to healthcare is limited.

"Our oral contraceptive program is both a mission-driven commitment to improving access to family planning worldwide and a powerful proof point for the LYNX platform," Dr. Hackett noted. The Gates Foundation grant validates this potential impact, signaling a strong belief that this technology can advance global health equity by providing women with a more reliable and discreet contraceptive option.

The road ahead for Nortiva is complex. It must navigate the specific FDA regulatory pathways for novel drug-device combinations, scale complex manufacturing processes, and convince a market accustomed to daily pills and long-acting injectables. However, with a clinically validated platform, a clear strategic vision, deep-pocketed backing from Innoviva, and a mission-driven flagship program, Nortiva Bio is poised to write the next chapter in oral drug delivery.